|
36 |
Cleanrooms: solving the mystery of recurring low level contamination
|
sureAssist |
2024-12-26 |
117 |
|
35 |
The possible Impact of Artificial Intelligence on the Role of the Qualified Person
|
sureAssist |
2024-12-26 |
121 |
|
34 |
Preparing A framework For Artificial Intelligence And Machine Learning Validation: A 3-Step Approach
|
sureAssist |
2024-12-26 |
133 |
|
33 |
CGMP Requirements For Automated Facility Monitoring Systems
|
sureAssist |
2024-12-26 |
124 |
|
32 |
RTU vs concentrate disinfectants: efficiency as a factor in selection
|
sureAssist |
2024-12-26 |
127 |
|
31 |
EMA phases out extraordinary COVID-19 regulatory flexibilities
|
sureAssist |
2024-12-26 |
122 |
|
30 |
6 Ways To Achieve Manufacturing Audit And Inspection Readiness
|
sureAssist |
2024-12-26 |
124 |
|
29 |
FDA issues draft guidance on reporting manufacturing changes for gene therapies
|
sureAssist |
2024-12-26 |
120 |
|
28 |
Aseptic filling PUPSIT: What is it? Should I? Must I? How do I? Where do I?
|
sureAssist |
2024-12-26 |
128 |
|
27 |
FDA now also assesses Countries and Regions as a Risk Factor
|
sureAssist |
2024-12-26 |
122 |
